BVT 115959

Drug Profile

BVT 115959

Alternative Names: BVT.115959; CBT-1008

Latest Information Update: 24 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Biotechnology
  • Developer Swedish Orphan Biovitrum
  • Class Analgesics
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory pain; Neuropathic pain

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 07 Apr 2008 Efficacy data from a phase II trial in Neuropathic pain released by Biovitrum
  • 14 Dec 2007 Preclinical trials in Inflammatory pain in the United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top